Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VTGN | PRESS-RELEASE | neutral | 4/10 | Vistagen reported Q1 FY2027 results with a net loss of $0.30 per share, beating consensus of -$0.36 by 16.7%, and revenu | Aug 14, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 6/10 | TOMI Environmental Solutions reported Q2 2026 revenue of $2.25M (+118% YoY) and EPS of $(0.05), beating consensus of $(0 | Aug 14, 2026 |
| CLNN | PRESS-RELEASE | mixed | 7/10 | Clene reported Q2 2026 results with a GAAP net loss of $13.4M ($1.08/share), significantly missing the $0.37 consensus d | Aug 14, 2026 |
| MBRX | PRESS-RELEASE | mixed | 6/10 | Moleculin Biotech reported Q2 2026 results with a net loss of -$1.40/share, beating the -$1.55 consensus, and highlighte | Aug 14, 2026 |
| ALLR | PRESS-RELEASE | neutral | 4/10 | Allarity Therapeutics reported Q2 2026 results with a net loss of $3.4M (vs $2.3M in Q2 2025), driven by higher interest | Aug 14, 2026 |
| HELP | PRESS-RELEASE | bullish | 7/10 | Helus Pharma reported Q4 fiscal 2026 (period ended March 31, 2026) EPS of -$1.17, beating consensus of -$1.38 by 15.5%. | Aug 14, 2026 |
| REPL | PRESS-RELEASE | bullish | 7/10 | Replimune reported a modest EPS beat ($-0.72 vs $-0.77 consensus) for Q1 FY2026, but the headline is the FDA accelerated | Aug 14, 2026 |
| QNCX | PRESS-RELEASE | bullish | 6/10 | Quince Therapeutics reported Q2 2026 results highlighting a strengthened balance sheet with $116M cash following the Orp | Aug 14, 2026 |
| GTBP | PRESS-RELEASE | bearish | 5/10 | GT Biopharma reported Q2 2026 EPS of -$0.11, missing consensus of -$0.08 by 37.5%, with no revenue. Cash runway of $5.1M | Aug 14, 2026 |
| PMVP | PRESS-RELEASE | bullish | 6/10 | PMV Pharma reported Q2 2026 EPS of -$0.34, beating the -$0.38 consensus by 10.5%, and completed enrollment for the prima | Aug 14, 2026 |
| EVAX | PRESS-RELEASE | neutral | 1/10 | Evaxion announced it will report its Q2 2026 results on August 20, 2026. | Aug 14, 2026 |
| GALT | PRESS-RELEASE | bullish | 8/10 | Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headli | Aug 14, 2026 |
| HURA | PRESS-RELEASE | neutral | 3/10 | TuHURA Biosciences reported Q2 2026 financial results with no revenue or EPS, as the company remains pre-revenue. Cash s | Aug 14, 2026 |
| LNTH | PRESS-RELEASE | bullish | 7/10 | Lantheus received FDA approval for TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for evaluating Alzheimer's di | Aug 14, 2026 |
| OTLK | PRESS-RELEASE | mixed | 7/10 | Outlook Therapeutics reported a GAAP net loss of $0.15 per share for Q3 FY2026, significantly missing the consensus esti | Aug 14, 2026 |
| RNTX | PRESS-RELEASE | bullish | 6/10 | Rein Therapeutics reported Q2 2026 GAAP EPS of -$0.10, beating consensus of -$0.27 by 63%, driven by lower operating exp | Aug 14, 2026 |
| ANL | PRESS-RELEASE | bullish | 6/10 | Adlai Nortye reported H1 2026 results with revenue of $13.1M (from nil) from an AN9025 license agreement, net loss narro | Aug 14, 2026 |
| QNTM | PRESS-RELEASE | bullish | 7/10 | Quantum BioPharma reported Q2 2026 EPS of -$0.71, a 21% miss vs consensus of -$0.59, but the headline event is the FDA c | Aug 14, 2026 |
| NMRA | PRESS-RELEASE | neutral | 4/10 | Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalen | Aug 14, 2026 |
| TVRD | PRESS-RELEASE | mixed | 5/10 | Tvardi Therapeutics reported Q2 2026 EPS of -$0.73, a 15.6% miss vs consensus of -$0.63, with no revenue. Pipeline progr | Aug 14, 2026 |
| ACXP | PRESS-RELEASE | mixed | 5/10 | Acurx Pharmaceuticals reported Q2 2026 EPS of -$0.53, a 26% miss versus the $0.42 consensus, reflecting higher R&D spend | Aug 14, 2026 |
| FATE | PRESS-RELEASE | bullish | 5/10 | Fate Therapeutics announced first patient dosed in the Phase 2 potentially registrational RECLAIM-LN trial of FT819 for | Aug 14, 2026 |
| ZNTL | PRESS-RELEASE | bearish | 6/10 | Zentalis Pharmaceuticals priced an underwritten public offering of 23 million shares at $3.50 per share, expecting ~$80. | Aug 13, 2026 |
| BBIO | PRESS-RELEASE | bearish | 5/10 | BridgeBio announced a secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P., with the company receiving no | Aug 13, 2026 |
| GNLX | PRESS-RELEASE | neutral | 4/10 | Genelux reported Q2 2026 net loss of $0.21 per share, slightly below the $0.20 consensus estimate. The pre-revenue clini | Aug 13, 2026 |
| CLDI | PRESS-RELEASE | mixed | 5/10 | Calidi Biotherapeutics reported Q2 2026 results with a narrowed net loss of $4.2M ($2.94/share) vs $5.7M ($31.75/share) | Aug 13, 2026 |
| TIL | PRESS-RELEASE | neutral | 4/10 | Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2 2025, driven by sharply | Aug 13, 2026 |
| TPST | PRESS-RELEASE | bearish | 7/10 | Tempest Therapeutics reported Q2 2026 net loss of $5.2M ($0.34/share), a narrower loss vs $7.9M ($2.07) a year ago, but | Aug 13, 2026 |
| INBX | PRESS-RELEASE | bearish | 6/10 | Inhibrx reported Q2 2026 EPS of -$2.34, a 26.5% miss vs the -$1.85 year-ago period, and zero revenue (vs $1.3M in Q2 202 | Aug 13, 2026 |
| NKTR | PRESS-RELEASE | bullish | 7/10 | Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue of $10.1M (slightly | Aug 13, 2026 |